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CHARACTERISTICS COMPARED TO THOSE THAT HAVE POSITIVE FETAL 
FIBRONECTIN RESULTS? 
 
ELISABETH BELISLE 
ABSTRACT 
Objective: The fetal fibronection (fFN) test is an excellent test to rule out preterm 
birth (PTB) as it has a negative predictive value of 98-99%. However, some 
patients in this group of women still deliver preterm, which puts the infant at risk 
for many chronic complications such as cerebral palsy and developmental delay. 
To date, there is limited data about PTB in the setting of a negative fFN. The 
purpose of this study is to look at maternal, fetal, and placental characteristics of 
women who had a spontaneous preterm delivery (PTD) with a negative fFN test 
and compare them with maternal, fetal, and placental characteristics of women 
who had a spontaneous PTD with a positive fFN test. 
Methods: This retrospective chart review was conducted at Baystate Medical 
Center between 2006 and 2009. Women were included in the study if they 
delivered within 14 days of the fFN test at this institution. Demographic 
characteristics, clinical antecedents for delivery, and placenta pathology reports 
were compared between women with a positive fFN test and a negative fFN test. 
Clinical antecedents for delivery were either (a) Preterm premature rupture of 
membranes (PPROM) leading to preterm labor (PTL) (b) abruption leading to 
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PTL or (c) idiopathic PTL.  Placenta histological reports were reviewed and 
organized into the following categories (a) normal placenta (b) evidence of 
inflammation (c) evidence of ischemic changes or (d) evidence of both 
inflammation and ischemic changes. Comparison between groups was 
conducted using Wilcoxon rank sum test and Fisher’s exact test. 
Results: A total of 82 women had fFN testing and delivered preterm. Of these, 
58 women had spontaneous PTL and a placental pathology report. Demographic 
characteristics were found to be similar between the two groups. Women with a 
positive fFN test were found to deliver earlier (p=0.038). Overall, there was a 
trend toward an increase in placental ischemic changes in the fFN negative 
group (68.8% versus 23.8%) but this did not achieve statistical significance.   
Conclusion: Women delivering spontaneously preterm after a positive fFN test 
may have different pregnancy characteristics than women delivering 
spontaneously preterm after a negative fFN test. Women in the positive fFN test 
group tended to deliver earlier than women in the negative fFN test group, 
suggesting that the mechanism contributing to PTB is likely to be different 
between the two groups. The data suggests that there is a trend toward women 
with a negative fFN having placental ischemic changes.  More studies should be 
done to see if this trend continues. Clinically, this information would be helpful 
because these women may not be a good candidate for this test and may need 
to be hospitalized and given steroid treatment when showing signs of PTL. 
However, until further information is available, women with suspected ischemic 
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placentas should not yet be excluded from fFN testing. Clearly, further studies 
are needed to explore the relationship between placental ischemia and fFN 
testing. 
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Background 
Preterm Birth (PTB) 
 A typical length of a pregnancy is about 40 weeks (280 days from the 
first day of the last menstrual period) or three trimesters (Simhan et al., 2012). 
This allows the fetus enough time to remain in the womb while the development 
of the brain, heart, skin, lungs, and more takes place (Simhan et al., 2012). 
Although, this is the average time period that is expected, each pregnancy is a 
unique experience and many women will give birth either before or after 40 
weeks. A pregnancy reaches term when the fetus is delivered between 37 and 
41 weeks gestation (Iams and Romero, 2007). A pregnancy that reaches term is 
associated with a low risk for adverse neonatal outcomes (Simhan et al., 2012). 
When a woman gives birth prior to 37 weeks gestation, this is defined as a 
preterm birth (PTB) (Simhan and Caritis, 2007). PTB refers to the birth of a baby 
who is born too early and, as a result, is at high risk for significant chronic 
medical complications which range from vision and hearing impairment, 
development delay, cerebral palsy, pulmonary insufficiency, to even death (Iams 
and Romero, 2007; Leveno et al., 2010).  
 Specifically, Simhan, Iams, and Romero (2012) state that there an 
inverse relationship between chronic medical complications and gestational age, 
meaning that as gestational age decreases, the risk for infant morbidity 
increases. Essentially, the less developmental progress made while in the womb, 
the more difficulty that infant will have (Figure 1) (Bender, 2001). These 
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difficulties are not only extremely emotionally taxing for families, but are also 
economically taxing. In the United States, the cost of PTB was estimated to 
exceed $26.2 billion or $51,600 per infant in the year 2005 (National Research 
Council, 2007).  
 According to the National Center for Health Statistics, the percentage of 
PTB’s in the United States has continued to increase from 11.6% to 12.7% 
between 2000 and 2005 (MacDorman and Mathews, 2008). It is important to 
note that in 2005, 68.8% of all infants who did not survive to his or her first 
birthday were preterm infants (Table 1) (MacDorman and Mathews, 2008). In 
2006, a study by Callaghan et al., assessed the contribution of PTB to infant 
mortality rates in the United States and showed that among all causes of death 
for infants, the leading cause was complications associated with prematurity 
(Callaghan et al., 2006; Simhan et al., 2012).   
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Figure 1 Fetal development and corresponding prospective survival. The 
average length of pregnancy is 40 weeks, divided into three trimesters. During 
this time, the fetus remains in the womb while making developmental progress. If 
expelled too early, the fetus is a risk for significant health complications 
depending on the time point within the pregnancy. Figure taken from Bender, 
2001 at http://www.hawaii.edu/malamalama/2001/01/Pretermbirth.html. 
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Table 1 Infant mortality rates by gestational age. The number of infant deaths 
varies by gestational age showing the highest mortality for infants born preterm. 
Infants born preterm that do survive are at risk for significant complications such 
as developmental delay, cerebral palsy, and pulmonary insufficiency. Figure 
taken from Leveno et al.  (2010) in Williams Obstetrics. 
 
Infant Mortality Rates in the United States in 2005 
 Live Birth No. (%) Infant Deaths No. (%) 
Total infants 4,138,573 (100) 28,384 (100) 
Gestational age at Birth  
 
 
<32 weeks 83,428 (2) 15,287 (54) 
32-33 weeks 65, 853 (1.6) 1099 (4) 
34-36 weeks 373,663 (9) 1727 (10) 
37-41 weeks 3,346,237 (81) 8116 (29) 
≥42 weeks 239,850 (6) 637 (2) 
Unknown 29,542 (0.7) 516 (2) 
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Medically Indicated PTB versus Spontaneous PTB 
 PTBs have been classified into two main overarching categories: 
medically indicated PTBs and spontaneous PTBs (Iams, 2002). Twenty percent 
of PTBs are medically indicated (Norwitz, 2013). This occurs when the physician 
deems delivery of the fetus necessary because of medical complications that 
compromise maternal well-being or fetal well-being (Iams and Romero, 2007). 
These issues include, but are not limited to, intrauterine growth restriction where 
the fetus is not growing appropriately for gestational age, non-reassuring fetal 
testing where the fetus is thought to be at risk for fetal death, and preeclampsia 
(hypertensive disorders of pregnancy) (Iams and Romero, 2007; Norwitz, 2013).  
 The majority of PTBs (80%) occur spontaneously (Iams, 2002). Women 
with signs and symptoms of PTL often have one or more of the demographic 
characteristics listed in Table 2 (Simhan et al., 2012). These characteristics 
include African American race, low socioeconomic status, poor prenatal care, 
history of a prior PTB, cigarette smoking, substance abuse, and cervical/uterine 
abnormalities (Simhan et al., 2012; Norwitz, 2013). In a perfect world, identifying 
women with these characteristics may help to prevent PTB, however; many 
PTB’s occur in women who have no apparent risk factors (Simhan et al., 2012; 
Norwitz, 2013).  
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Table 2 Demographic profile of women with spontaneous preterm birth 
Women with a spontaneous PTB may have these characteristics. However, half 
of women with a spontaneous PTB have no known risk factors. Table adapted 
from Simhan et al., 2012. 
 
Demographic Profile of Women with Spontaneous Preterm Birth 
• History of genital tract colonization, infection, or instrumentation 
o Urinary tract infection and bacteriuria 
o Sexually transmitted infections such as Chlamydia, gonorrhea, human 
papillomavirus, or Trichomonas 
o Bacterial vaginosis 
o Cervical dysplasia and treatment for same 
o Spontaneous or induced abortion 
• African American 
• Bleeding of uncertain origin in pregnancy 
• History of a previous spontaneous preterm birth 
• Uterine anomaly 
• Assisted fertility care 
• Multifetal gestation 
• Cigarette smoking, substance abuse 
• Poor nutrition and low prepregnancy weight (body mass index <19.6) 
• Periodontal disease 
• Limited education, low income, and low social status 
• Late registration for prenatal care 
• High levels of personal stress in one or more domains of life 
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Preterm Labor (PTL) Syndrome 
 In 1994, Romero et al. proposed that labor after 37 weeks gestation 
(term labor) and labor prior to 37 weeks gestation (preterm labor) share a 
common endpoint, which first begins with uterine contractility, cervical changes, 
and ends with separation and rupture of fetal membranes  (Romero et al., 1994). 
However, activation of labor prior to 37 weeks is thought to be inherently 
different. The initiation of PTL was proposed to be the result of a pathological 
process rather than a physiological process (Romero et al., 1994). It was also 
proposed that PTL may be in response to multiple inciting factors and thus the 
term “Preterm Labor Syndrome” was coined (Romero et al., 1994). These factors 
include PTL due to microorganisms producing chemicals that can induce the 
process, disruption of the blood supply to the placenta, overdistension and 
stretching of the uterus (due to multiple gestations, too much fluid in the amniotic 
sac, etc.), uterine abnormalities, allergic mechanisms (due to chemicals released 
by mast cells), and fetal development and growth disorders (Romero et al., 1994; 
Iams and Romero, 2007; Simhan et al., 2012) (Figure 2).  
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Figure 2 Causes of preterm labor syndrome. Figure taken from Iams and 
Romero, 2007. The causes of PTL are multiple and include infection such as 
chorioamnionitis, ischemia, growth and development (endocrine) disorders, 
overdistension of the uterus, uterine abnormalities, cervical insufficiency and 
allergies. To date, some factors that cause PTL syndrome remain unknown 
(Romero et al., 1994). 
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Tocolysis and Corticosteroids for Treatment of PTL 
PTL is defined as cervical dilation with maternal contractions before 37 
weeks gestation is reached (American College of Obstetricians and 
Gynecologists, 2003; Simhan et al., 2012). Not all patients that present to the 
hospital with PTL will go on to deliver preterm (King et al., 1988). It is important to 
distinguish those patients with PTL that will lead to PTB, so that they receive 
treatment to avoid the newborn complications of prematurity (Simhan et al., 
2012). In order to avoid the complications associated with prematurity, patients 
with symptoms of PTL are admitted to the hospital for prolonged observation, 
tocolysis, and corticosteroid treatment (King et al., 1988; Simhan and Caritis, 
2007; Simhan et al., 2012).  
Tocolytics are medications that are given to stop contractions of the uterus 
long enough to administer corticosteroids (Leveno et al., 2010). Corticosteroids, 
act on type 1 and type 2 alveolar cells, which are cells in the lungs that work to 
improve gas exchange and produce surfactant, respectively (Lee and Guinn, 
2013). This is important because surfactant reduces resistance and surface 
tension in the lungs, allowing the fetus to breathe much easier. Ultimately, 
steroids reduce the incidence of respiratory distress syndrome (RDS) (Figure 3) 
(Lee and Guinn, 2013). Additional studies have found that steroids have been 
associated with a reduction in systemic infection in the first 48 hours of life, 
intraventricular hemorrhage, necrotizing entercolitis, and neonatal mortality (Lee 
and Guinn, 2013). This is possibly due to improvement of fetal respiratory status 
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but may also be due to the effects of steroid regulation on additional genes in the 
genome (Lee and Guinn, 2013).  
Like every other medication, tocolytics and corticosteroids are not without 
risk. Magnesium sulfate, terbutaline, nifedipine, and indomethacin are common 
agents used to prevent PTB (Gibson, 2011). Side effects of tocolytics include, but 
are not limited to, complications such as maternal tachycardia, hyperkalemia, 
hyperglycemia, neonatal hypoglycemia and ileus (Simhan et al., 2012). Common 
dosage and additional side effects are noted in Table 3 (Gibson, 2011). While a 
single course of corticosteroids may be considered if a woman is likely to deliver 
within the next week, multiple courses are not recommended due to the increase 
in risk for reduced fetal growth and adverse brain effects (Simhan et al., 2012; 
Lee and Guinn, 2013).  
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Figure 3 Model for corticosteroid action on type II alveolar cells. 
Glucocorticoids are corticosteroids that act on surfactant producing cells in the 
lungs. Surfactant reduces resistance and surface tension in the lungs. 
Glucocorticoids also help type 1 alveolar cells, which help with gas exchange. 
Overall, glucocorticoids help reduce the incidence of RDS (Simhan et al., 2012; 
Lee and Guinn 2013). Figure taken from Lee and Guinn, UpToDate, 2013.  
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Table 3 Common tocolytic agents. Tocolytic agents are given to inhibit uterine 
contractions long enough for clinicians to administer corticosteroids. These 
agents are known to have life-threatening side effects and should only be used 
when needed. Many women who present with signs and symptoms of PTL are 
given tocolytics but end up delivering at term (Simhan et al., 2012). Table 
modified from Gibson, 2011 in U.S. Pharmacist. 
 
Common Tocolytic Agents 
Agent Common Dosage Side Effects 
Magnesium 
Sulfate 
4 to 6 g IV bolus 
followed by 2 to 3 
g per hour IV 
infusion 
May cause maternal flushing, lethargy, 
headache, weakness, dry mouth, 
pulmonary edema, cardiac arrest, may 
cause neonatal lethargy, hypotonia, 
respiratory depression 
Terbutaline 0.25 mg SC every 
20 min to 3 h or 
2.5 to 10 mcg per 
min continuous 
infusion, gradually 
increased to 17.5 
to 30 mcg per min 
May cause maternal cardiac 
arrhythmias, pulmonary edema, 
myocardial ischemia, hypotension, 
tachycardia, metabolic abnormalities, 
nausea, vomiting, fever, hallucination, 
may cause neonatal tachycardia, 
hypoglycemia, hypocalcemia, 
hyperbilirubinemia, hypotension, 
intraventricular hemorrhage  
Nifedipine 30 mg po followed 
by 10 to 20 mg q 4 
to 6 h 
May cause maternal flushing, 
headache, dizziness, nausea, 
transient hypotension 
Indomethacin 50 mg rectally or 
50 to 100 mg po 
followed by 25 to 
50 mg po q 4 to 6 
h for 48 h 
May cause maternal nausea, 
heartburn; may cause neonatal 
constriction of ductus arteriosus, 
pulmonary hypertension, decreased 
renal function, intraventicular 
hemorrhage, hyperbilirubinemia, 
necrotizing entercolitis 
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Introduction 
Limitations in Predicting PTB 
To date, a clinician’s ability to determine whether PTL will result in PTB is 
limited (King et al., 1988). Up to 50% of patients in controlled clinical trials 
admitted for tocolysis who received placebo went on to deliver at term (King et 
al., 1988). Thus, a large numbers of obstetrical patients who are destined to 
deliver at term, but present with symptoms of PTL, potentially receive treatments 
with possible life-threatening side effects (King et al., 1988). In addition to 
maternal and fetal health effects of these treatments, hospital visits are very 
expensive (King et al.,1988; National Research Council, 2007). Therefore, 
methods to detect women who are truly at risk for delivering early would be 
beneficial (King et al., 1988; Peaceman et al., 1997; National Research Council, 
2007; Lockwood and Barss, 2013).  
 
Fetal Fibronectin Testing 
 Traditional methods to predict whether a woman was destined to deliver 
preterm relied on clinical indicators such as obstetrical history or symptoms 
(Lockwood and Barss, 2010). However, neither is very reliable. A number of 
biological markers in serum, amniotic fluid, and cervical secretions have been 
evaluated for their potential to predict PTB (Leitich et al., 1999; Lockwood and 
Barss, 2013). One excellent biochemical approach for predicting PTB is the 
measurement of fetal fibronectin (fFN) in the cervico-vaginal secretions (Leitich et 
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al., 1999). 
fFN is a glycoprotein that acts as a glue to help adhere the placenta to the 
uterine lining (Peaceman et al., 1997; Hologic, 2010; Lockwood and Barss 2013) 
(Figure 3). fFN appears in cervico-vaginal secretions normally until about 20 
weeks gestation, is absent from 22 to 35 weeks, and reappears as a woman 
approaches her 40th week of pregnancy (Hologic, 2010; Peaceman et al., 1997) 
(Figure 4). The presence of fFN in the cervix or the vagina after the 20th week of 
pregnancy is abnormal and may indicate a disruption of the attachment of 
membranes (Peaceman et al., 1997; Hologic, 2010).  
Clinical evidence supports the use of fFN as a marker for PTD. Peaceman 
et al. found that patients who had both symptoms of PTL and the presence of 
fFN in vaginal secretions were at an increased risk for PTD within 14 days 
(Peaceman et al., 1997). Peaceman et al also found that women who tested fFN 
negative were not likely to deliver within 7 days (negative predictive value=99%) 
(Peaceman et al., 1997). In this way, fFN is known as a biochemical marker that 
allows us to differentiate those who are at high risk for PTD and those who are 
not (Peaceman et al., 1997; Hologic, 2010; Lockwood and Barss, 2013). 
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Figure 4 Connection of the placenta to the uterine lining by fetal 
fibronectin. fFN is the glue between the fetal membranes (which include the 
amnion and the chorion) and the uterine wall (known as the decidua). Between 
22 to 35 weeks gestation, this glycoprotein should be absent in cervico-vaginal 
secretions. When fFN is found during this time, a woman is at an increased risk 
for early delivery (Peaceman et al., 1997). Figure taken from Lockwood and 
Barss, 2013, UpToDate. 
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Figure 5 Fetal Fibronectin concentration in ng/mL by gestational age in 
weeks. Between 22 and 35 weeks gestational age, fFN should not be detected in 
cervico-vaginal secretions. However, a concentration of 50 ng/mL of fFN present 
in secretions is considered positive and indicates a woman is at an increased risk 
for early delivery. Figure taken from Hologic, 2010, 
www.ffntest.com/info/fetal_test/what_fetal.htm 
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Candidates for Fetal Fibronectin Testing 
 The fFN test is a United States Food and Drug Administration (FDA) 
approved test performed when women have clinical symptoms suggestive of PTL 
(Lockwood and Barss, 2013). The test is performed using a swab to collect a 
sample during a speculum examination (Lockwood and Barss, 2013). Candidates 
for this test should have intact fetal membranes because amniotic fluid does 
contain the fFN protein and could give a false positive result (Lockwood and 
Barss, 2013). The patient should also be between 22 and 35 weeks gestation 
because fFN should not be detected during this time period (Lockwood and 
Barss, 2013). Cervical dilation should be less than 3 centimeters as well 
(Lockwood and Barss, 2013).  The test is considered positive when the 
concentration of fFN is greater than 50 ng/mL  (Lockwood and Barss, 2013). 
 
Utility of Fetal Fibronectin Testing 
fFN testing can be a good tool for distinguishing the differences between 
those cases with false versus true PTL (Peaceman et al., 1997). If women test 
positive, they are more likely to deliver in the near future and should be admitted 
to the hospital for further observation (Peaceman et al., 1997). 
However, a negative test, associated with a negative predictive value 
around 99%, highly suggests that women are not likely to deliver within 14 days 
(Peaceman et al., 1997). Therefore, when a woman tests negative and has other 
reassuring factors, obstetricians feel confident that PTD is not imminent and thus 
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they are comfortable in sending patients home with no intervention (Peaceman et 
al., 1997; Lockwood and Barss, 2013). This can prevent unnecessary 
interventions such as hospital admission or medications (Peaceman et al., 1997). 
However, despite the high negative predictive value of fFN screening, a negative 
fFN test does not eliminate the possibility of PTD as there are still occasional 
patients who deliver early regardless of test results (King et al., 1988). To date, 
little is known about false negatives. The advantage of knowing what type of 
pregnancies would be at the greatest risk for a false negative is important 
because false negatives in this clinical condition could result in suboptimal 
obstetrical care. The patient would not get the treatment that would help reduce 
the risks of prematurity (Iams and Romero, 2007). 
Specific Aims/Objectives 
 Although the fFN test has a negative predictive value of 99%, there 
are still a small percentage of women who deliver early (Peaceman et al., 1997). 
To date, there is limited data about PTB in the setting of a negative fFN. This 
project aims to retrospectively look at singleton, spontaneous PTD’s at Baystate 
Medical Center within 14 days of fFN testing. 
Specifically, 
1. This study intends to compare all maternal, fetal, and placental 
characteristics of women with a negative test and compare them with 
maternal, fetal, and placental characteristics of women with a positive test.  
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2. This study intends to assess clinical antecedents for delivery in the two 
groups. 
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Methods 
 
This retrospective chart review was conducted at Baystate Medical Center 
(BMC) between 2006 and 2009.  All charts for women who had an fFN assay 
drawn during the eligible time period were reviewed. Data was abstracted from 
the medical record and reviewed by a trained research assistant. Women were 
included in the study if they delivered an infant within 14 days of the fFN test at 
BMC. Women were excluded from the study if they had a fetus with fetal 
anomolies, fetal demise, or maternal and fetal medical indications for delivery 
such as preeclampsia or non-reassuring fetal status.  
Of the 82 women who delivered a singleton at BMC less than 14 days 
after a fFN test, 24 were excluded: 1 woman was excluded because the neonate 
had Trisomy 21, 1 woman was excluded because she had a fetal demise, 1 
woman did not have a placenta pathology report, 11 women delivered for 
maternal indications, and 10 women delivered for fetal indications. This left 58 
women who delivered a preterm singleton sponanteously within 14 days of an 
fFN test.   
This study was approved by the Institution Review Board at Baystate 
Medical Center.  
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Study Measures 
Fetal Fibronectin Assays  
Fetal fibronectin assays were performed using the Adeza Biomedical 
Rapid TLi system (Adeza Biomedical Corporation, Sunnyvale, California). The 
samples were collected as recommended by the manufacturer, that is, prior to a 
digital cervical exam, vaginal probe ultrasound, or the collection of other vaginal 
specimens. The last fFN result was used if a woman had multiple tests. Women 
who had contaminated results were excluded.  
 
Clinical Antecedents for Delivery 
Clinical antecedents for delivery among the two groups were among the 
following categories (a) Preterm premature rupture of membranes (PPROM) 
leading to PTL, (b) Abruption leading to PTL or (c) Idiopathic PTL.  PPROM was 
defined as rupture of membranes before the onset of labor and before 37 weeks 
gestation. Histological evidence of abruption was confirmed by the pathologist 
and with the physician’s clinical impression found in the patient’s chart. Women 
who came to the hospital with symptoms of PTL with no known cause were 
categorized into the idiopathic PTL group.  
 
Placental Analysis 
Placentas were analyzed according to the institutional protocol for 
placenta histological analysis. All reports were reviewed by a single board 
certified pathologist. Placenta histological results were placed into the following 
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categories: (a) normal placenta, (b) evidence of inflammation, (c) evidence of 
ischemic changes or (d) evidence of both inflammation and ischemic changes. 
Inflammation was categorized as in Akers et al., (2007): acute chorioamnionitis, 
funisitis, or acute deciduitis. Acute chorioamnionitis was defined as presence of 
multiple neutrophilic infiltrates within and beneath the chorionic plate. Funisitis 
was defined as the presence of neutrophils in the other vessel layers, migrating 
out of an umbilical vessel and into Wharton’s jelly. Acute deciduitis was defined 
as multifocal neutrophilic infiltrates within the maternal decidua (Akers et al., 
2007). Cases were excluded that showed evidence of inflammation that was 
more likely to be the result of labor rather than the cause (i.e. acute 
chorioamnionitis that was found to be rising from the rupture site was more likely 
to be found as a result of labor rather than chorioamnionitis that was found over 
the entire membranes).  
Placentas were put in the ischemic category if they showed signs of stress 
classified by any of the following: (a) infarcts, (b) nucleated red blood cells, (c) 
accelerated maturation, (d) uneven villous maturation, (e) villous edema,  (f) 
syncytial knots or (g) abruption. Infarcts were defined as deposition of dense 
fibrinoid layer on the placental basal plate that acts to block normal maternal 
blood flow. Accelerated maturation of villi was defined as a preterm placenta 
having villous morphology approaching term, which was not consistent with 
gestational age. Syncytial knots are defined as aggregates of syncytial nuclei at 
the surface of terminal villi. Uneven maturation was defined as a preterm 
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placenta having certain areas of villous morphology approaching term, which was 
not consistent with gestational age. Villous edema was defined as diffuse 
multifocal edema affecting the immature intermediate villi of the placenta. 
Abruption was defined as histological basal plate disruption associated with 
retroplacental organized blood, placental villous compression, and focal increase 
in syncytialtrophoblastic knotting, focal trophoblastic necrosis, and villous 
agglutination without infarct. Normal placentas had neither inflammatory changes 
nor ischemic changes.  
 
Statistical Analysis 
 
 The Fisher exact test was used to compare catagorical variables (clinical 
antecedents leading to PTD results and placenta pathology catagory results). 
The Student t test was used to calculate means for normally distributed 
continuous variables and the Wilcoxon rank-sum test was used for not normally 
distributed continuous variables. Significance was set a p <0.05. Statistical 
analysis was performed using STATA.   
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Results 
 
Table 4 shows the demographic characteristics such as maternal age, 
birthweight of the fetus, maternal race, parity, and duration between fFN test and 
delivery for all 58 subjects who met study inclusion criteria. The two groups of 
women (fFN positive versus fFN negative) had similar demographic 
characteristics. Women tended to be in their mid-twenties, were predominately 
white, and had given birth before (multiparous). As expected, women in the fFN 
positive group tended to deliver a few days earlier than women who test fFN 
negative (5 days versus 8 days), and this was statistically significant (p=0.038).  
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Table 4 Demographic characteristics for eligible women based on fFN 
results –The characteristics between the fFN positive and fFN negative groups 
are statistically similar except duration between fFN test and delivery.  
 
 
Characteristics 
 
Negative fFN 
n=16 
n (%) 
 
Positive fFN 
n=42 
n (%) 
 
p-value 
 
Maternal Age 
 
26.9± 6.1 
 
26.2±6.5 
 
0.72 
 
Birthweight  
 
2166.19±380.7 
 
1838.54±592.9 
 
0.13 
 
Race 
   
0.34 
      
White 
 
8 (50.0) 
 
16 (38.1) 
 
0.79 
      
     Black 
 
3 (18.8) 
 
13 (31.0) 
 
      
     Hispanic 
 
4 (25.0) 
 
10 (23.8) 
 
      
     Unknown 
 
1 (6.2) 
 
3 (7.1) 
 
 
Parity 
   
0.77 
      
     Nulliparous 
 
5 (31.2) 
 
15 (36.6) 
 
      
     Multiparous 
 
11 (68.8) 
 
26 (63.4) 
 
 
Duration between 
fFN test and 
delivery 
 
7.88± 4.5 
 
5.20±3.76 
 
0.038 
 
 
 
 
 
 
 
 
 
 
 
	  	   26 
Clinical Antecedents for Delivery 
There was no statistical difference in the cause for spontaneous PTB. 
Overall, clinical antecedents for delivery were largely due to idiopathic PTL 
between the two groups (52.4% of women with a positive fFN versus 62.5% of 
women with a negative fFN). PPROM accounted for 42.9% of women with a 
positive fFN versus 37.5% of women with a negative fFN. Placental abruption 
accounted for the smallest percentage of deliveries (4.8% of women with a 
positive fFN versus 0% of women with a negative fFN) (Table 5).  
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Table 5 Clinical antecedents leading to preterm delivery- Clinical 
antecedents leading to PTD were categorized into the following three categories: 
PPROM, Abruption, and Idiopathic PTL. Women who delivered for fetal or 
maternal medical indications were not included in this study. 
 
 
Clinical 
antecedent 
 
 
fFN negative 
n=16 
n (%) 
 
fFN positive 
n=42 
n (%) 
 
p-value 
 
PPROM 
 
 
6 (37.5) 
 
18 (42.9) 
 
0.88 
 
Abruption 
 
 
- 
 
2 (4.8) 
 
 
Idiopathic PTL 
 
 
10 (62.5) 
 
22 (52.4) 
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Placental Pathology  
There was a trend toward an increase in evidence of placental ischemic 
changes in the negative fFN group. 68.8% of women in the fFN group had 
evidence of ischemia as compared with 28.6% of women in the positive fFN 
group, but this did not achieve statistical significance. 12.5% of women who had 
a negative fFN test had a normal placenta as compared to 23.8% of women who 
had a positive fFN test. 6.2% of women with a negative fFN had histological 
evidence of inflammation as compared to 11.9% of women who had a positive 
fFN test. 12.5% of women who had a negative fFN test showed both 
inflammation and ischemic changes upon histological analysis versus 35.7% 
women who had a positive fFN test. These results were not statistically 
significant (Table 6).  
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Table 6 Placenta pathology categories- Patient pathology reports were 
reviewed for histological evidence of inflammation, ischemia, both inflammation 
and ischemic changes, or neither inflammation or ischemia. Placentas with 
neither inflammatory nor ischemic changes were categorized as normal. 
 
 
Placenta pathology 
 
fFN negative 
n=16 
n (%) 
 
fFN positive 
n=42 
n (%) 
 
P-value 
 
Normal 
 
2 (12.5) 
 
10 (23.8) 
 
0.062 
 
Inflammation 
 
1 (6.2) 
 
5 (11.9) 
 
 
Ischemia 
 
11 (68.8) 
 
12 (28.6) 
 
 
Ischemia and 
Inflammation 
 
2 (12.5) 
 
15 (35.7) 
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Discussion 
 
This study was initiated with the specific aim of comparing pregnancy 
characteristics of women with a positive fFN test and a negative fFN test within 
14 days of a spontaneous PTD. Clinically, this would be useful because there 
may be some additional factors that would exclude women from being a 
candidate for this type of testing. Clinical evidence suggests that a fFN test 
should be given to women with signs and symptoms of PTL (Peaceman et al., 
1997; Leitich et al., 1999; Lockwood and Barss, 2013) fFN is considered positive 
when the concentration is greater than 50 ng/mL in the cervicovaginal fluid. 
Women with a positive test should be hospitalized for observation and would be 
candidates for tocolytics and corticosteroids, in order to decrease the 
complications associated with PTB (Simhan et al., 2012). In the setting of a 
negative fFN test, PTB is unlikely and there is no need for hospitalization and 
medical intervention (Simhan et al., 2012). Although very unlikely, a negative fFN 
test does not eliminate any possibility of delivery and some women will go on to 
deliver preterm. This may have an unfortunate impact on the infant since 
corticosteroids may not have been administered which would reduce 
complications associated with prematurity. Due to the very low incidence of PTB 
after a negative fFN, data regarding specific characteristics of this population are 
limited. 
In this study, the demographic characteristics of the women in the two 
groups were statistically similar with age, race, and infant birth weight. However, 
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going along with what would be expected, the timing of delivery after an fFN test 
was different between the two groups. Women in the positive fFN test group 
tended to deliver earlier than women in the negative fFN test group. This 
suggests that the mechanism contributing to PTB may be different between the 
two groups.  
Past researchers have tried to understand the mechanism behind fFN 
release. In the literature, it was previously thought that histological evidence of 
placental inflammation at delivery was a separate finding from a positive fFN test 
result (Goldenberg et al., 1996; Rizzo et al., 1997; Yoon et al., 2001; Akers et al., 
2007). One group of researchers thought that the two findings were not a 
coincidence—that is, they thought that the inflammation may have disrupted the 
fFN and allowed it to be detected in cervico-vaginal secretions (Akers et al., 
2007). Therefore, Akers et al performed a study to determine if women with 
placental inflammation were more likely to have a positive fFN result (Akers et 
al., 2007). In this study, Akers et al. categorized placentas as having 
inflammation if they showed any signs of the following: chorioamnionitis, funisitis, 
deciduitis, and microabcess formation (Akers et al., 2007). The authors ultimately 
concluded that women with a positive fFN were not more likely to have placental 
inflammation as noted by histological evidence at delivery (Akers et al., 2007). In 
this study, the criteria of Akers et al were used to categorize placentas as having 
inflammation. 
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No studies have been done specifically looking at histological evidence of 
placental ischemia and fFN result. However, based on other studies that looked 
at placental ischemic changes, the following were used for this category (a) 
infarcts, (b) nucleated red blood cells, (c) accelerated maturation of villi, (d) 
uneven villous maturation, (e) villous edema, (f) syncytial knots, and (g) 
abruption. Several studies have been done looking at placental ischemic 
changes and fetal outcomes which all utilized the same markers of placental 
ischemic changes as identified above by our pathologist (Salafia et al., 1995). 
The choices for markers of placental ischemia were made based on the 
following known scientific data: (a) Infarcts are associated with PTD and act to 
block normal maternal blood flow (Leveno et al., 2010).  (b) Nucleated red blood 
cells are found due the exposure of the bone marrow and other sites of fetal 
hematopoiesis (the liver) in response to persistent and significantly decreased 
levels oxygen, which stimulate increased production and premature release of 
red blood cells into the periphery (Redline, 2013). (c) Accelerated maturation of 
villi within the placenta could be a marker of poor perfusion because the placenta 
has certain villous morphology approaching term rather than villous morphology 
of a preterm placenta (Benirschke and Kaufmann, 1990). (d) Uneven villous 
maturation within the placenta is similar to accelerated villous maturation within 
the placenta where the whole placenta shows villous morphology approaching 
term rather than the morphology of a preterm placenta. This is a marker of poor 
perfusion (Benirschke and Kaufmann, 1990). (e) Villous edema is seen as a 
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placental response to fetal stress and is associated with fetal hypoxia due to 
compression of the blood vessels within the edematous villous (Naeye, 1992). (f) 
Syncytial knots are increased in amount within the placenta as oxygen tension 
decreases (Benirschke and Kaufmann, 1990) (g) Abruption refers to bleeding at 
the decidual-placental interface which causes partial to total placental 
detachment prior to delivery of the fetus, which inhibits the exchange of gases 
and nutrients (Ananth and Kinzler, 2013).  
The sample size in this study presents a limitation to the interpretation of 
the results obtained. Peaceman et al found that the negative predictive value for 
fFN testing is 98-99%, meaning that women who test fFN negative tend not to 
deliver within 14 days of testing (Peaceman et al., 1997). In translation, it is a 
rare event for a woman to test fFN negative and still deliver preterm (it represents 
about 1% of women). Due to the nature of this event, it is difficult to increase the 
sample size and look at women in this category. With three years of data, we 
found 16 women who tested negative yet still delivered. However, a strength of 
this study is for all of those women included in the study only one did not have 
data for placental analysis. 
From this dataset, there is a trend suggesting that women delivering 
preterm after a negative fFN test are more likely to have placental ischemic 
changes. Although this relationship was not found to be statistically significant, 
due to the limited numbers, we may not have been able to have enough power in 
order to achieve statistical significance. More studies should be done to see if 
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this trend continues. Clinically, this information would be helpful because these 
women may not be a good candidate for this test and may need to be 
hospitalized and given steroid treatment when showing signs of PTL. However, 
until further information is available, women with suspected ischemic placentas 
should not yet be excluded from fFN testing. Clearly, further studies are needed 
to explore the relationship between placental ischemia and fFN testing. 
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Conclusion and Future Directions 
Overall, this study of 58 women suggests that women with a negative fFN 
who still deliver within 14 days of testing tend to have histological evidence of 
ischemic changes within the placenta (68.8%). This was a pilot study done to 
compare specific pregnancy characteristics in women with a positive or negative 
fFN test.  Since a trend was found with women who had a PTD after a negative 
fFN test having ischemic changes within the placenta, the study will be expanded 
to include births from January 2010- December 2013 at BMC. 
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